Pfizer Inc. (NYSE:PFE) said it is planning on presenting the results of its Community-Acquired Pneumonia Immunization Trial in Adults study next month, and that it may have significant impact on preventing community-acquired pneumonia for seniors. Pfizer Inc. (NYSE:PFE) stock opened at $31.87 in last session, and closed at $32.23, while the day range of Pfizer Inc. (NYSE:PFE) stock is $31.83 – $32.24. The stock showed a positive weekly performance of 2.16%.
The analysts at Leerink Swann are adding $5 billion to Merck & Co., Inc. (NYSE:MRK) projected revenue in 2020, much of it based on fast-swelling expectations of the success of an experimental cancer therapy, MK-3475, that’s in a tight race with two other PD-1/PD-L1 drugs to the FDA. But Leerink is also adding $2.4 billion in projected sales for Merck’s all-oral hepatitis C cocktail–which is in a second wave of interferon-free cocktails that are already beginning to radically reconfigure the mass therapeutic market. Merck & Co., Inc. (NYSE:MRK) stock opened at $56.24 in last session, and closed at $56.66 by gaining 0.69%. The 52 week range of $42.27 – $56.92. Company’s market capitalization is $167.66B.
Johnson & Johnson (NYSE:JNJ) the world’s most trusted pharmaceutical and baby care goods manufacturer, has launched “Name our Future” social media campaign, celebrating the 30 millionth Malaysian baby who will be born in the coming days. Johnson & Johnson (NYSE:JNJ) stock increased 0.27% and finished the last session at $91.36. The EPS of the stock remained 4.81. Company’s market capitalization is $262.39B.
Bristol-Myers Squibb Company (NYSE:BMY) announced that the U.S. Food and Drug Administration (FDA) has granted its investigational DCV Dual Regimen (daclatasvir and asunaprevir) Breakthrough Therapy Designation for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV). The designation is based on data from the company’s ongoing Phase III clinical trial program evaluating the all-oral combination regimen of DCV, an investigational NS5A replication complex inhibitor, and ASV, an investigational NS3 protease inhibitor, without ribavirin. Bristol-Myers Squibb Co (NYSE:BMY) stock opened the session at $53.56, and closed the session at $53.95. The 52 week range of the Bristol-Myers Squibb Co (NYSE:BMY) stock remained $36.31 – $56.83 and the day range was $53.50 – $54.10.
Leave a Reply